Re: GRAS Notice No. GRN 000845

Dear Ms. Gregoire:

The Food and Drug Administration (FDA, we) is granting the request on behalf of Chr. Hansen A/S (Chr. Hansen) to cease our evaluation of GRN 000845, which we filed on April 24, 2019. We received this request on September 5, 2019.

The subject of the notice is *Lactobacillus rhamnosus* LGG for use as an ingredient in food, including: milk and dairy products, such as yogurt and other fermented milk products; dairy alternatives (fermented oat milk, fermented soy milk, fermented almond milk, fermented coconut milk); beverages such as juice and protein shakes; shelf-stable products such as bars (granola bars, protein bars, meal replacement bars); confectionery (gummy candy, hard candy, soft chew candy, chewing gum, coatings); breakfast cereals at a level up to $10^{10}$ cfu/serving throughout the shelf life of the product. The notice informs us of Chr. Hansen's view that these uses of *L. rhamnosus* LGG are GRAS through scientific procedures.

In a letter dated September 5, 2019, Chr. Hansen stated that since the submission of the GRAS notice, there is new information relevant to the accuracy and identity of the notified substance and data from studies has been published. Because of this additional published information, Chr. Hansen requested that we cease to evaluate GRN 000845 in order for Chr. Hansen to review the new publications to ensure that a future notice is complete and resubmit at a future date.

In accordance with 21 CFR 170.275(b)(3), the text of this letter responding to GRN 000845 is accessible to the public at www.fda.gov/grasnoticeinventory.

Sincerely,

Susan J. Carlson -S

Susan Carlson, Ph.D.
Director
Division of Food Ingredients
Office of Food Additive Safety
Center for Food Safety
and Applied Nutrition